|
|||||
|
|
Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences |
|
| Authors: | Michael Horowitz MBBS PhD Vanita R. Aroda MD Jenny Han MS Elise Hardy MD Chris K. Rayner MBBS PhD |
| Affiliation: | 1. Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia;2. Community Clinical Research Center, MedStar Health Research Institute, Hyattsville, Maryland;3. Pharmapace, San Diego, California;4. Clinical Research, AstraZeneca, Gaithersburg, Maryland |
| Abstract: | |
| Keywords: | adverse events exenatide gastrointestinal disorders GLP‐1 receptor agonists liraglutide type 2 diabetes |